<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04026789</url>
  </required_header>
  <id_info>
    <org_study_id>2019P000848</org_study_id>
    <nct_id>NCT04026789</nct_id>
  </id_info>
  <brief_title>Medication Abortion for Pregnancy of Unknown Location</brief_title>
  <acronym>MAPUL</acronym>
  <official_title>Medication Abortion for Pregnancy of Unknown Location</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Planned Parenthood League of Massachusetts</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Planned Parenthood League of Massachusetts</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare time to completed abortion between two protocols for
      patients seeking medication abortion - same-day start versus delay-for-diagnosis - in the
      setting of asymptomatic, low-risk, pregnancy of unknown location.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 17, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized controlled trial (plus prospective cohort for those interested in participation but unwilling to be randomized)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to completed abortion</measure>
    <time_frame>through study completion, an average of two weeks</time_frame>
    <description>Time to completed abortion as defined by the number of days between initial ultrasound diagnosis of PUL to the diagnostic test that confirms complete abortion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with complete expulsion of pregnancy without surgical intervention</measure>
    <time_frame>14 days after initiation of medical abortion</time_frame>
    <description>Efficacy of medical abortion, defined as number of participants with complete expulsion of pregnancy without surgical intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to diagnosis of pregnancy outcome</measure>
    <time_frame>Within 2 weeks of identification of pregnancy of unknown location on ultrasound</time_frame>
    <description>Number of days between initial ultrasound diagnosis of pregnancy of unknown location and diagnosis of pregnancy outcome, with options including intrauterine pregnancy, ectopic pregnancy, or early pregnancy loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ectopic pregnancy</measure>
    <time_frame>Within 2 weeks of identification of pregnancy of unknown location on ultrasound</time_frame>
    <description>Rate of ectopic pregnancy among entire study population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of participants who complete follow-up and confirm complete abortion</measure>
    <time_frame>Within 1 month of identification of pregnancy of unknown location on ultrasound</time_frame>
    <description>Percent of participants who adhered to recommended follow-up plan and confirmed a complete abortion through ultrasound or hCG</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Pregnancy Related</condition>
  <arm_group>
    <arm_group_label>Same-day-start</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delay-for-diagnosis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Same-day-start</intervention_name>
    <description>Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing</description>
    <arm_group_label>Same-day-start</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Delay-for-diagnosis</intervention_name>
    <description>Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion</description>
    <arm_group_label>Delay-for-diagnosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients with an undesired pregnancy of less than or equal to 42 days gestation based on
        last menstrual period (LMP) who present to Planned Parenthood League of Massachusetts
        (PPLM)'s Greater Boston Health Center seeking medication abortion will be considered for
        study participation.

        Inclusion criteria:

          -  Positive urine or serum hCG test

          -  No evidence of gestational sac on transvaginal ultrasound

          -  Desire for medication abortion as method of pregnancy termination

        Exclusion criteria:

          -  Ineligible for medication abortion at PPLM based on current PPLM clinical guidelines

          -  Reasonable clinical suspicion for ectopic or molar pregnancy, such as abnormal or
             concerning ultrasound findings

          -  High risk for ectopic pregnancy, such as prior ectopic pregnancy, history of tubal
             surgery, concurrent intrauterine device in place during this pregnancy

          -  Exhibiting symptoms of possible ectopic, such as vaginal bleeding or abdominal pain

          -  LMP &gt; 42 days or unknown LMP

          -  Age less than 18 years

          -  Prior participation in this study

          -  Anticipated inability to present for scheduled follow-up visits
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Principal Investigator</last_name>
    <phone>6176161600</phone>
    <email>research@pplm.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>PPLM</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Manager</last_name>
      <phone>617-616-1600</phone>
      <email>research@pplm.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We do not plan to share individual participant data with any other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

